Acomplete list of authors and centers is available in the Appendix as a supplementary file.
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study
Article first published online: 3 JUL 2012
© 2012 International Society on Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis
Volume 10, Issue 7, pages 1297–1302, July 2012
How to Cite
DENTALI, F., POLI, D., SCODITTI, U., MINNO, M. N. D. D., STEFANO, V. D., SIRAGUSA, S., KOSTAL, M., PALARETI, G., SARTORI, M. T., GRANDONE, E., VEDOVATI, M. C., AGENO, W. and for the CEVETIS (CErebral VEin Thrombosis International Study) investigators (2012), Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. Journal of Thrombosis and Haemostasis, 10: 1297–1302. doi: 10.1111/j.1538-7836.2012.04774.x
- Issue published online: 3 JUL 2012
- Article first published online: 3 JUL 2012
- Accepted manuscript online: 11 MAY 2012 12:45PM EST
- Received 21 December 2011, accepted 30 April 2012
Vol. 11, Issue 2, 399, Article first published online: 7 FEB 2013
- anticoagulant treatment;
- cerebral vein thrombosis;
Summary. Background: Little information is available on the long-term clinical outcome of cerebral vein thrombosis (CVT).
Objectives and methods: In an international, retrospective cohort study, we assessed the long-term rates of mortality, residual disability and recurrent venous thromboembolism (VTE) in a cohort of patients with a first CVT episode.
Results: Seven hundred and six patients (73.7% females) with CVT were included. Patients were followed for a total of 3171 patient-years. Median follow-up was 40 months (range 6, 297 months). At the end of follow-up, 20 patients had died (2.8%). The outcome was generally good: 89.1% of patients had a complete recovery (modified Rankin Score [mRS] 0–1) and 3.8% had a partial recovery and were independent (mRS 2). Eighty-four per cent of patients were treated with oral anticoagulants and the mean treatment duration was 12 months. CVT recurred in 31 patients (4.4%), and 46 patients (6.5%) had a VTE in a different site, for an overall incidence of recurrence of 23.6 events per 1000 patient-years (95% confidence Interval [CI] 17.8, 28.7) and of 35.1 events/1000 patient-years (95% CI, 27.7, 44.4) after anticoagulant therapy withdrawal. A previous VTE was the only significant predictor of recurrence at multivariate analysis (hazard ratio [HR] 2.70; 95% CI 1.25, 5.83).
Conclusions: The long-term risk of mortality and recurrent VTE appears to be low in patients who survived the acute phase of CVT. A previous VTE history independently predicts recurrent events.